Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration
Xiang W, Cheong J, Ang S, Teo B, Xu P, Asari K, Sun W, Than H, Bunte R, Virshup D, Chuah C. Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. Oncotarget 2015, 6: 33769-33780. PMID: 26378050, PMCID: PMC4741801, DOI: 10.18632/oncotarget.5615.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine TriphosphateAnimalsAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsApoptosisbeta CateninBlast CrisisCasein Kinase ICell Line, TumorCell ProliferationDasatinibHumansInhibitory Concentration 50K562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiceMice, SCIDMitochondriaNeoplasm TransplantationPhosphorylationPyrvinium CompoundsRNA InterferenceConceptsChronic phase chronic myeloid leukemiaTyrosine kinase inhibitorsBCR-ABL1 tyrosine kinase inhibitorsMitochondrial respirationInduce apoptosisBP-CMLBlast phaseFDA-approved anthelminthic drugBCR-ABL1Casein kinase 1aMyeloid leukemiaEffects of pyrviniumTargeting mitochondrial respirationInhibition of mitochondrial respirationCD34+ progenitor cellsInhibit mitochondrial respirationBP-CML patientsCD34+ cellsChronic myeloid leukemiaCord blood CD34Inhibited tumor growthSelf-renewal capacityWnt/b-catenin signaling pathwayInhibited colony formationKinase 1A
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply